{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:32:23Z","timestamp":1769848343192,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"DOI":"10.7759\/cureus.102656","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T18:13:02Z","timestamp":1769796782000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Sacubitril\/Valsartan Versus Enalapril in the Treatment of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Rayan","family":"Aljubeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saif","family":"Almuzainy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Lemine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majed","family":"Bseiso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Kadro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Metawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan","family":"Qaisar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2023.05","article-title":"Global public health burden of heart failure: an updated review","volume":"9","author":"Shahim B","year":"2023","unstructured":"Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: an updated review. Card Fail Rev. 2023, 9:e11. 10.15420\/cfr.2023.05","journal-title":"Card Fail Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.6515\/ACS.202503_41(2).20241023A","article-title":"Does the Naples prognostic score predict long-term mortality in patients with advanced-stage heart failure?","volume":"41","author":"Tatar S","year":"2025","unstructured":"Tatar S, Kan H, Sahin AT, Sertdemir AL, \u0130cli A, Akilli H. Does the Naples prognostic score predict long-term mortality in patients with advanced-stage heart failure?. Acta Cardiol Sin. 2025, 41:210-8. 10.6515\/ACS.202503_41(2).20241023A","journal-title":"Acta Cardiol Sin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022, 145:e895-1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy SP","year":"2020","unstructured":"Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a review. JAMA. 2020, 324:488-504. 10.1001\/jama.2020.10262","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987, 316:1429-35. 10.1056\/NEJM198706043162301","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","unstructured":"SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991, 325:293-302. 10.1056\/NEJM199108013250501","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-318811","article-title":"Management of heart failure with reduced ejection fraction","volume":"108","author":"Haydock PM","year":"2022","unstructured":"Haydock PM, Flett AS. Management of heart failure with reduced ejection fraction. Heart. 2022, 108:1571-9. 10.1136\/heartjnl-2020-318811","journal-title":"Heart"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000092457","article-title":"Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase","volume":"103","author":"Maric C","year":"2006","unstructured":"Maric C, Zheng W, Walther T. Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase. Nephron Physiol. 2006, 103:149-56. 10.1159\/000092457","journal-title":"Nephron Physiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-004-0460-0","article-title":"Molecular physiology of natriuretic peptide signalling","volume":"99","author":"Kuhn M","year":"2004","unstructured":"Kuhn M. Molecular physiology of natriuretic peptide signalling. Basic Res Cardiol. 2004, 99:76-82. 10.1007\/s00395-004-0460-0","journal-title":"Basic Res Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023950","article-title":"Use and out-of-pocket cost of sacubitril-valsartan in patients with heart failure","volume":"11","author":"Shore S","year":"2022","unstructured":"Shore S, Basu T, Kamdar N, et al.. Use and out-of-pocket cost of sacubitril-valsartan in patients with heart failure. J Am Heart Assoc. 2022, 11:e023950. 10.1161\/JAHA.121.023950","journal-title":"J Am Heart Assoc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48623","article-title":"Comparison of outcomes between sacubitril\/valsartan and enalapril in patients with heart failure: a systematic review and meta-analysis","volume":"15","author":"Reyaz I","year":"2023","unstructured":"Reyaz I, Kaur A, Saad MZ, et al.. Comparison of outcomes between sacubitril\/valsartan and enalapril in patients with heart failure: a systematic review and meta-analysis. Cureus. 2023, 15:e48623. 10.7759\/cureus.48623","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan X","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014, 14:135. 10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne JA","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, et al.. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011, 343:d4002. 10.1136\/bmj.d4002","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2076","article-title":"OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction","volume":"23","author":"Piepoli MF","year":"2021","unstructured":"Piepoli MF, Hussain RI, Comin-Colet J, Dosantos R, Ferber P, Jaarsma T, Edelmann F. OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. Eur J Heart Fail. 2021, 23:127-35. 10.1002\/ejhf.2076","journal-title":"Eur J Heart Fail"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2021.05.005","article-title":"Sacubitril\/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: a randomized, double-blind, active-controlled study","volume":"239","author":"Dos Santos MR","year":"2021","unstructured":"Dos Santos MR, Alves MNN, Jord\u00e3o CP, et al.. Sacubitril\/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: a randomized, double-blind, active-controlled study. Am Heart J. 2021, 239:1-10. 10.1016\/j.ahj.2021.05.005","journal-title":"Am Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez EJ","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al.. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019, 380:539-48. 10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16332","article-title":"Comparison of sacubitril\/valsartan versus enalapril in the management of heart failure","volume":"13","author":"Bano S","year":"2021","unstructured":"Bano S, Bai P, Kumar S, et al.. Comparison of sacubitril\/valsartan versus enalapril in the management of heart failure. Cureus. 2021, 13:e16332. 10.7759\/cureus.16332","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12034","article-title":"The comparative effects of sacubitril\/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction","volume":"12","author":"Zhao Y","year":"2022","unstructured":"Zhao Y, Tian LG, Zhang LX, et al.. The comparative effects of sacubitril\/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction. Pulm Circ. 2022, 12:e12034. 10.1002\/pul2.12034","journal-title":"Pulm Circ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai AS","year":"2019","unstructured":"Desai AS, Solomon SD, Shah AM, et al.. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019, 322:1077-84. 10.1001\/jama.2019.12843","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-0854","article-title":"Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction - results from the PARALLEL-HF study","volume":"85","author":"Tsutsui H","year":"2021","unstructured":"Tsutsui H, Momomura SI, Saito Y, et al.. Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction - results from the PARALLEL-HF study. Circ J. 2021, 85:584-94. 10.1253\/circj.CJ-20-0854","journal-title":"Circ J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2355","article-title":"A randomized clinical trial on the short-term effects of 12-week sacubitril\/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study","volume":"23","author":"Halle M","year":"2021","unstructured":"Halle M, Sch\u00f6bel C, Winzer EB, Bernhardt P, Mueller S, Sieder C, Lecker LSM. A randomized clinical trial on the short-term effects of 12-week sacubitril\/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study. Eur J Heart Fail. 2021, 23:2073-82. 10.1002\/ejhf.2355","journal-title":"Eur J Heart Fail"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2022.04.003","article-title":"Safety and efficacy of ARNI (valsartan\/sacubitril) vs ACEI (enalapril) in acute heart failure - a prospective observational study","volume":"74","author":"Bhat TS","year":"2022","unstructured":"Bhat TS, Hafeez I, Tak SF, et al.. Safety and efficacy of ARNI (valsartan\/sacubitril) vs ACEI (enalapril) in acute heart failure - a prospective observational study. Indian Heart J. 2022, 74:178-81. 10.1016\/j.ihj.2022.04.003","journal-title":"Indian Heart J"},{"key":"ref24","article-title":"A comparative analysis of the clinical efficacy of sacubitril valsartan sodium and enalapril in patients with non-valvular ejection fraction reduction in heart failure","volume":"30","author":"Zhang Q","year":"2024","unstructured":"Zhang Q, Wang J, Da Y, Li X, Pan L. A comparative analysis of the clinical efficacy of sacubitril valsartan sodium and enalapril in patients with non-valvular ejection fraction reduction in heart failure. Altern Ther Health Med. 2024, 30:250-6.","journal-title":"Altern Ther Health Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-020-00440-y","article-title":"The AWAKE-HF study: sacubitril\/valsartan impact on daily physical activity and sleep in heart failure","volume":"21","author":"Khandwalla RM","year":"2021","unstructured":"Khandwalla RM, Grant D, Birkeland K, Heywood JT, Fombu E, Owens RL, Steinhubl SR. The AWAKE-HF study: sacubitril\/valsartan impact on daily physical activity and sleep in heart failure. Am J Cardiovasc Drugs. 2021, 21:241-54. 10.1007\/s40256-020-00440-y","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101598","article-title":"Sacubitril\/valsartan vs ACE inhibitors or ARBs: a systematic review and meta-analysis of randomized trials","volume":"4","author":"Evbayekha E","year":"2025","unstructured":"Evbayekha E, Idowu AB, LaRue S. Sacubitril\/valsartan vs ACE inhibitors or ARBs: a systematic review and meta-analysis of randomized trials. JACC Adv. 2025, 4:101598. 10.1016\/j.jacadv.2025.101598","journal-title":"JACC Adv"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon SD","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, et al.. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019, 381:1609-20. 10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"key":"ref28","article-title":"Sacubitril-valsartan","author":"Nicolas D","year":"2025","unstructured":"Nicolas D, Patel P, Reed M. Sacubitril-valsartan. StatPearls. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000473","article-title":"Limitations of sacubitril\/valsartan in the management of heart failure","volume":"24","author":"Yandrapalli S","year":"2017","unstructured":"Yandrapalli S, Aronow WS, Mondal P, Chabbott DR. Limitations of sacubitril\/valsartan in the management of heart failure. Am J Ther. 2017, 24:e234-9. 10.1097\/MJT.0000000000000473","journal-title":"Am J Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1670","article-title":"Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study","volume":"22","author":"Senni M","year":"2020","unstructured":"Senni M, Wachter R, Witte KK, et al.. Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. Eur J Heart Fail. 2020, 22:303-12. 10.1002\/ejhf.1670","journal-title":"Eur J Heart Fail"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer M","year":"2015","unstructured":"Packer M, McMurray JJ, Desai AS, et al.. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015, 131:54-61. 10.1161\/CIRCULATIONAHA.114.013748","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.2566","article-title":"Effects of sacubitril\/valsartan on all-cause hospitalizations in heart failure: post hoc analysis of the PARADIGM-HF and PARAGON-HF randomized clinical trials","volume":"9","author":"Lu H","year":"2024","unstructured":"Lu H, Claggett BL, Packer M, et al.. Effects of sacubitril\/valsartan on all-cause hospitalizations in heart failure: post hoc analysis of the PARADIGM-HF and PARAGON-HF randomized clinical trials. JAMA Cardiol. 2024, 9:1047-52. 10.1001\/jamacardio.2024.2566","journal-title":"JAMA Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi JL Jr","year":"2019","unstructured":"Januzzi JL Jr, Prescott MF, Butler J, et al.. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019, 322:1085-95. 10.1001\/jama.2019.12821","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/396207-efficacy-and-safety-of-sacubitrilvalsartan-versus-enalapril-in-the-treatment-of-heart-failure-with-reduced-ejection-fraction-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T18:13:03Z","timestamp":1769796783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/396207-efficacy-and-safety-of-sacubitrilvalsartan-versus-enalapril-in-the-treatment-of-heart-failure-with-reduced-ejection-fraction-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.102656","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}